Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer

O’Flaherty, John D.; Gray, Steven G.; Richard, Derek J.; Fennell, Dean A.; O’Leary, John; Blackhall, Fiona; O’Byrne, Kenneth J.

doi:10.1016/j.lungcan.2011.10.018

Cited by 152 publications

(119 citation statements)

References 84 publications

Supporting

Mentioning

116

Contrasting

Unclassified

Order By: Relevance

“…Como alternativa a la muestra tisular, hay un creciente interés en el estudio de biopsias líquidas o muestras sanguíneas del paciente, mediante la caracterización molecular de células tumorales circulantes (CTC) y el escrutinio del ADN libre circulante (cfDNA) en el suero 48,49 . El estudio de las CTC en cáncer de pulmón ha sido menos exhaustivo que en otros tipos tumorales 50 . Su recuento pudiera tener utilidad pronóstica y en la monitorización de la respuesta a tratamientos.…”

Section: ¿Cuáles Son Las Aplicaciones De La Biopsia Líquida?unclassified

Actualización de las recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón avanzado de célula no pequeña. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica

López‐Ríos

Castro

Concha

et al. 2015

Revista Española de Patología

View full text Add to dashboard Cite

Section: ¿Cuáles Son Las Aplicaciones De La Biopsia Líquida?unclassified

Actualización de las recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón avanzado de célula no pequeña. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica

López‐Ríos

Castro

Concha

et al. 2015

Revista Española de Patología

View full text Add to dashboard Cite

“…Identification and characterization of CTCs are often named as non-invasive "liquid biopsy", which could represent phenotype and genotype of the primary tumor and/or distant metastases. The CTCs are detectable in blood and they are rare cells even in patients with advanced cancer (~1-100 CTCs per 10 9 blood cells) [53,54]. Several studies have shown that CTCs may be considered as prognostic markers for NSCLC patients.…”

Section: Circulating Tumor Cells (Ctcs)mentioning

confidence: 99%

“…Results from several studies demonstrate that CTCs can be a biomarker of disease progression indicating an early metastatic spread as well as guides of treatment decisions. It must be noted that "anti-CTC" therapy may be a future strategy in preventing of metastases formation [53].…”

Section: Circulating Tumor Cells (Ctcs)mentioning

confidence: 99%

The role of genetic and other biomarkers in NSCLC prognosis

et al. 2014

View full text Add to dashboard Cite

AbstractThe development of non-small-cell lung cancer (NSCLC) is a multistep process, which is triggered and maintained by various factors. Many steps of non-small-cell lung carcinogenesis, risk factors and biomarkers have been identified; however no consistent model has been established of personalized medicine for these patients. Distinct various gene expression, products of mutated genes and other markers such as circulating nucleic acids or tumor cells has been proven to be potential biomarkers of non-small cell lung cancer as well as potential targets for new treatment strategies. This article will highlight promising biomarkers in non-small cell lung cancer prognosis.

show abstract

“…Metastatic disease results in a large number of cancer related deaths. Most of lung cancer patients are diagnosed with advanced disease, and some with early stage disease have high recurrence rates [1].…”

Section: Introductionmentioning

confidence: 99%

“…Development of an effective enrichment process has become critical for detecting CTCs. In recent years, many technologies www.impactjournals.com/oncotarget to effectively capture CTCs from blood have proven useful [1]. The magnetic bead labeled with antibodies against epithelial cell adhesion molecule (EpCAM) CTC detecting methods are widely used.…”

Section: Introductionmentioning

confidence: 99%

Introducing, OncoTarget

Blagosklonny¹,

Gudkov²

2010

Oncotarget

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) have attracted pretty much attention from scientists because of their important relationship with the process of metastasis. Here, we developed a size-based microfluidic chip containing triangular pillar array and filter channel array for detecting single CTCs and CTC clusters independent of tumor-specific markers. The cell populations in chip were characterized by immune-fluorescent staining combining an epithelial marker and a mesenchymal marker. We largely decreased the whole time of detection process to nearly 1.5h with this microfluidic device. The CTCs were subsequently measured in 77 patients with lung cancer and 39 healthy persons. The microfluidic device allowed for the detection of CTCs with apparent high sensitivity and specificity (82.7% sensitivity and 100% specificity). Furthermore, the total CTC counts were found to be elevated in advanced patients with metastases when compared with those without (20.89±14.57 vs 8.428±5.858 cells/ mL blood; P<0.01). Combined epithelial marker and mesenchymal marker analysis of CTCs could provide more information about metastasis in patients than only usage of epithelial marker. In conclusion, the development of the size-based microfluidic device for efficient capture of CTCs will enable detailed characterization of their biological properties and values in cancer diagnosis.

show abstract

Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer

Cited by 152 publications

References 84 publications

Actualización de las recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón avanzado de célula no pequeña. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica

Actualización de las recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón avanzado de célula no pequeña. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica

The role of genetic and other biomarkers in NSCLC prognosis

Introducing, OncoTarget

Contact Info

Product

Resources

About